TLDR
- LLY stock fell ~2% after mixed weekly prescription data across its GLP-1 portfolio
- Foundayo recorded 3,707 prescriptions in its second week, up from 1,390 in week one
- Novo Nordisk’s oral Wegovy had 18,410 prescriptions in its second week for comparison
- Combined Mounjaro, Zepbound, and Foundayo prescriptions dipped 0.3% week-over-week
- Lilly maintains ~59% weekly new prescription market share in the GLP-1 category
Eli Lilly’s stock dipped around 2% on Thursday as investors digested the latest prescription numbers for its GLP-1 drug portfolio — and the early read on Foundayo wasn’t exactly a crowd-pleaser.
Foundayo, Lilly’s new oral weight loss pill, pulled in 3,707 total prescriptions in its second week on the market. That’s up from 1,390 in its debut week, but still well below the bar set by Novo Nordisk’s oral Wegovy, which logged 18,410 prescriptions in its own second week back in January.
RBC Capital Markets analyst Trung Huynh was blunt about the optics. “While we believe comparisons early into launch should be considered immaterial, Foundayo’s uptake this week is likely to be received negatively,” he said.
J.P. Morgan’s Chris Schott agreed the ramp is slower than Wegovy’s, but called it unsurprising. Wegovy had a head start and stronger brand recognition by the time Lilly’s pill arrived.
Foundayo was approved on April 1, 2026. Prescriptions went live on LillyDirect almost immediately, with shipping starting April 6. Broad retail pharmacy and telehealth access opened on April 9.
Lilly itself has warned investors not to read too much into the early weekly numbers. The company has said figures may not capture all pharmacy partners and are “best interpreted over time rather than as a complete count.”
Mounjaro and Zepbound Hold Steady
The injectable side of Lilly’s portfolio was more stable. Mounjaro hit 758,400 total prescriptions for the week of April 17, up from 749,500 the prior week. New Mounjaro prescriptions came in at 367,900, versus 361,700 the week before.
Zepbound was a touch softer. Total prescriptions fell to 615,300 from 632,500, though new prescriptions edged up to 350,600 from 346,400.
Combined, Lilly’s Mounjaro, Zepbound, and Foundayo franchise totaled 1,377,400 prescriptions — down 0.3% from 1,381,000 the prior week.
Market Share Holds at 59%
Despite the week-over-week dip, Lilly held its ground in the broader GLP-1 market. The company maintained roughly 59% weekly new prescription market share, unchanged from the prior week.
The overall GLP-1 category continued growing, up about 32% year-over-year.
Morgan Stanley analysts struck a more optimistic tone on the injectable side. “We see ~6% upside to ’26 M+Z ests,” the firm wrote, referring to 2026 estimates for Mounjaro and Zepbound.
Morgan Stanley is watching both drugs as key product cycles for Lilly, with a focus on how they shape overall category growth and market share going forward.
While Lilly’s stock was down around 2%, Novo Nordisk’s U.S.-listed stock was trading roughly 2% higher on the same prescription data — a split reaction that underlines how investors viewed the Foundayo versus Wegovy comparison.
Lilly’s injectable drugs remain the core of its GLP-1 business, and the Mounjaro and Zepbound numbers continued to show steady week-over-week growth as of April 17.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
